JZYY(SH:600750)2022-10-21 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥973,492,830.29, representing a year-over-year increase of 44.95%[7] - The net profit attributable to shareholders for the same period was ¥112,645,005.35, showing a decrease of 22.46% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥93,205,288.58, down 25.69% year-over-year[7] - The company reported a basic earnings per share of ¥0.18, a decrease of 21.74% compared to the same period last year[11] - Total operating revenue for the first three quarters of 2022 reached ¥2,874,367,383.35, a significant increase from ¥1,937,836,872.68 in the same period of 2021, representing a growth of approximately 48.7%[65] - Net profit for the third quarter of 2022 was ¥538,381,354.78, compared to ¥466,437,225.31 in the same quarter of 2021, reflecting a growth of approximately 15.4%[69] - The profit attributable to shareholders of the parent company for the third quarter of 2022 was ¥504,936,397.50, an increase from ¥451,831,116.71 in the previous year, marking a rise of about 11.8%[69] - The company reported a total profit of ¥642,082,256.09 for the third quarter of 2022, compared to ¥556,267,148.77 in the same quarter of 2021, representing an increase of about 15.4%[69] - The total comprehensive income for the period was CNY 538,381,354.78, an increase from CNY 466,437,225.31 in the previous year, representing a growth of approximately 15.4%[71] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,153,454,605.92, an increase of 2.60% from the end of the previous year[11] - The total liabilities as of the reporting date were ¥1,456,936,411.58, up from ¥1,415,111,640.54, indicating a rise of about 2.9%[62] - The total equity attributable to shareholders of the parent company was ¥4,106,814,784.16, compared to ¥4,003,034,097.91 in the previous year, reflecting an increase of approximately 2.6%[62] - The company's cash and cash equivalents increased to CNY 1,204,958,052.65 from CNY 1,046,084,852.69 year-over-year[57] - The total current assets reached CNY 4,073,306,960.02, slightly up from CNY 4,064,479,153.32 in the previous year[57] - The company's non-current assets totaled CNY 2,080,147,645.90, compared to CNY 1,933,121,095.06 at the end of 2021[60] - The total liabilities included accounts payable of CNY 174,210,393.33, which increased from CNY 163,094,814.55 year-over-year[60] - The company reported a significant increase in other payables, which reached CNY 797,242,140.95, up from CNY 625,563,238.17[60] Revenue Breakdown - The gross profit margin for the pharmaceutical industry segment was 66.80%, an increase of 0.56 percentage points year-over-year[18] - The revenue from non-prescription drugs was ¥2,008,238,596.27, with a year-over-year increase of 30.12%[18] - The company experienced a significant revenue increase of 134.16% in the prescription drug category, totaling ¥557,556,853.45[18] - The revenue from the North China region was ¥675,838,153.16, reflecting a year-over-year increase of 76.47%[17] - The company attributed the revenue growth primarily to the acquisition of Hais Pharmaceutical, which expanded the scope of consolidation[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,203[24] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.06% of the total shares[24] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 21,222,397 shares, representing 3.37%[24] Cash Flow and Investments - The net cash flow from operating activities was CNY 454,923,017.17, slightly down from CNY 462,330,380.86 in the same period last year[75] - Cash inflow from operating activities totaled CNY 2,811,749,322.38, compared to CNY 2,011,623,620.03 in the previous year, indicating a growth of about 39.8%[75] - The net cash flow from investing activities was CNY 199,336,385.74, a significant improvement from a negative CNY 754,158,348.62 in the previous year[75] - The company paid CNY 418,171,159.55 in dividends and interest, compared to CNY 176,028,635.25 in the previous year, reflecting an increase of approximately 137.0%[75] - The net increase in cash and cash equivalents for the period was CNY 237,358,072.28, contrasting with a decrease of CNY 541,137,940.43 in the previous year[77] Research and Development - Research and development expenses for the first three quarters of 2022 totaled ¥72,884,666.04, compared to ¥47,762,731.83 in 2021, showing an increase of approximately 52.6%[65] Share Capital Changes - The company completed the cancellation of 274,000 shares from an incentive plan, reducing the total share capital from 629,912,000 to 629,638,000 shares[30] - The company adjusted the purpose of 56,042 shares in the repurchase account to be used for capital reduction, further reducing the total share capital to 629,581,958 shares[30]